Syros Pharmaceuticals (SYRS) announced Wednesday positive initial data from its ongoing SELECT-AML-1 Phase 2 trial evaluating tamibarotene, in combination with venetoclax and azacitidine in newly diagnosed, unfit patients with acute myeloid leukemia or AML and RARA gene overexpression.
In pre-market activity on Nasdaq, the shares were gaining around 10 percent to trade at $3.09.
Tamibarotene is an oral, selective, retinoic acid receptor alpha or RAR agonist. Syros continues to enroll patients in SELECT-AML-1 and anticipates reporting updated data from the trial in 2024.
The company noted that SELECT-AML-1 is evaluating the safety and efficacy of tamibarotene in combination with venetoclax and azacitidine compared to venetoclax and azacitidine in approximately 80 patients randomized 1:1.
The trial is also evaluating the triplet regimen as a salvage strategy in patients in the control arm who do not respond to venetoclax and azacitidine. The primary endpoint of the trial is complete response rateor CR /complete response with incomplete hematologic recovery or Cri.
In December 2022, Syros reported data from the safety lead-in portion of SELECT-AML-1, in which five of six response evaluable patients achieved CR/CRi.
Thomas Cluzeau, Head of Hematology at Nice University Hospital, Cte d'Azur University in France, said, "Despite the recent advances in treatment for unfit AML patients, there remains a substantial need for options that offer higher response rates and improved overall survival, particularly for the one-third of patients who do not respond to existing standard-of-care. I believe tamibarotene may offer a significant therapeutic advance for the treatment of AML and I am eager to continue enrolling patients in the ongoing SELECT-AML-1 trial."
For More Such Health News, visit rttnews.com
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.